DUAL THERAPEUTICS
Dual Therapeutics is focused on producing therapeutics for prostate cancer, lung cancer, and acute lymphoblastic leukemia. Its small-molecule modulators are designed to simultaneously block multiple cancer-promoting pathways, especially those linked to growth and survival, thus allowing a more comprehensive assault on cancer cells without harming healthy cells.
DUAL THERAPEUTICS
Industry:
Biotechnology Life Science Therapeutics
Founded:
2012-01-01
Address:
Cleveland, Ohio, United States
Country:
United States
Total Employee:
1+
Status:
Closed
Total Funding:
6.63 M USD
Current Employees Featured
Founder
More informations about "Dual Therapeutics"
Dual Therapeutics, a New Oncology Start-up, Is Launched by …
Oct 9, 2013 “Dual Therapeutics is based around discoveries made at Mount Sinai by an interdisciplinary team of investigators with expertise in medicinal chemistry, cancer biology, …See details»
Dual Therapeutics Announces Oncology Strategic Collaboration …
January 8, 2016 - Dual Therapeutics, LLC (“Dual Therapeutics”) today announced a strategic collaboration with Bristol-Myers Squibb (NYSE: BMY) to advance small molecule compounds …See details»
Dual Therapeutics LLC - Drug pipelines, Patents, Clinical trials
Mar 10, 2025 Explore Dual Therapeutics LLC with its drug pipeline, therapeutic area, technology platform, 1 news, Disease Domain:Neoplasms, Technology Platform:Small molecule drug, …See details»
Bristol-Myers Squibb, Dual Therapeutics Launch $255 Million
Jan 11, 2016 Dual Therapeutics is an oncology start-up company developing novel therapeutics for prostate cancer, lung cancer, and acute lymphoblastic leukemia. Founded in 2013, the …See details»
BMS, Dual Therapeutics Launch Up-to-$255M+ Cancer Collaboration
Jan 8, 2016 Founded in 2013, Dual is a portfolio company of its lead investor BioMotiv, and focuses on developing new therapeutics for prostate cancer, lung cancer, and acute …See details»
Dual Therapeutics - 2025 Company Profile - Tracxn
Feb 27, 2025 Dual Therapeutics - Develops small molecule therapeutics for prostate cancer, lung cancer, and acute lymphoblastic leukemia. Raised a total funding of $6.38M over 2 …See details»
Dual Therapeutics - PitchBook
Dual Therapeutics General Information Description. Developer of novel therapeutics designed to treat cancer. The company's therapeutics are used treat prostate cancer, lung cancer and acute lymphoblastic leukemia, enabling …See details»
Dual Therapeutics - Funding, Financials, Valuation & Investors
Dual Therapeutics is focused on producing therapeutics for prostate cancer, lung cancer, and acute lymphoblastic leukemia.See details»
Dual Therapeutics LLC - BioCentury Company Profiles - BCIQ
Aug 8, 2018 Dual Therapeutics LLC - BioCentury Company Profiles for the biopharma industrySee details»
Dual Therapeutics, a New Oncology Start-up, is Launched by …
Oct 9, 2013 Dual Therapeutics is based on intellectual property exclusively October 9, 2013 - BioMotiv, a drug development accelerator based in Cleveland, and the Icahn School of …See details»
Dual: Multi-pronged attack - BioCentury
Jun 23, 2014 Dual Therapeutics LLC is developing first-in-class oral small molecules that directly activate protein phosphatase 2 to disrupt multiple cancer pathways simultaneously. By …See details»
DT-061 - Drug Targets, Indications, Patents - Synapse
Mar 29, 2025 PP2A activity decreased, while mTOR activity increased in both human and mouse aortas with MFS. Concordantly, oral administration of DT-061 increased PP2A …See details»
Dual Therapeutics - Products, Competitors, Financials, Employees ...
Jan 11, 2016 Dual Therapeutics is an oncology company developing therapeutics for prostate cancer, lung cancer, and acute lymphoblastic leukemia. Founded in 2013, the company's …See details»
Dual Therapeutics - Tech Stack, Apps, Patents & Trademarks
Dual Therapeutics is focused on producing therapeutics for prostate cancer, lung cancer, and acute lymphoblastic leukemia.See details»
Pioneering the Next Generation of ALS Therapeutics: Announcing …
Apr 25, 2025 Three research consortia have been awarded Target ALS funding this April to develop next-generation gene therapies for ALS through our latest grant initiative, Consortia …See details»
Systemic Therapy for Metastatic Bladder Cancer in 2016 and Beyond
Feb 29, 2016 He is part of the advisory board of Genentech, Merck and Novartis. He owns Dual Therapeutics. The authors have no other relevant affiliations or financial involvement with any …See details»
Antibody-Drug Conjugates | Sutro Biopharma, Inc.
Sutro’s technology can take ADCs a stage further, in this case enabling the creation of dual-warhead ADCs with two different cytotoxic agents attached to the targeting antibody, which …See details»
Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for …
Apr 7, 2025 SOUTH SAN FRANCISCO, Calif., April 07, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the …See details»
Neil Dhawan - CSO, Head of R&D, and Co-Founder - Crunchbase
Neil Dhawan is the CSO, Head of R&D, and Co-Founder of Totus Medicines. He previously worked at Dual Therapeutics LLC as a Co-Founder. Neil Dhawan attended Icahn School of …See details»
Dual Therapeutics - Contacts, Employees, Board Members
Dual Therapeutics is focused on producing therapeutics for prostate cancer, lung cancer, and acute lymphoblastic leukemia. New. Resources. ... Experience the new Crunchbase, powered …See details»